Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Arterial hypertension - clinical trials update 2022

Hypertension Research volume 45, pages 1140–1146 (2022)Cite this article

A Correction to this article was published on 15 July 2022

This article has been updated

Abstract

Hypertension is the most prevalent cardiovascular risk factor worldwide and is associated with increased cardiovascular morbidity and mortality. Despite the availability of multimodal therapeutic approaches, a large number of patients do not achieve guideline-recommended blood pressure targets, which reiterates the importance of continued research in the field. This article summarizes and discusses the most relevant clinical trials in hypertension research published in 2021 and 2022. The topics include new insights into treatment targets in the elderly, novel findings of salt consumption and lifestyle interventions in resistant hypertension, new evidence about early antihypertensive combination therapy and the use of angiotensin II receptor blocker neprilysin inhibitors in resistant hypertension, as well as data regarding the safety of antihypertensive drugs with respect to cancerogeneity and regarding the impact of acetaminophen, a commonly used pain medication, on blood pressure. Finally, we provide an update on recent evidence on renal denervation and its role in current hypertension management.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Change history

References

  1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–88.

    Article  Google Scholar 

  2. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. Authors/Task Force Members:. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041.

    Article  CAS  Google Scholar 

  3. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159–219.

    Article  Google Scholar 

  4. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. STEP study group. trial of intensive blood-pressure control in older patients with hypertension. N. Engl J Med 2021;385:1268–79.

    Article  CAS  Google Scholar 

  5. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr., Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998;279:839–46.

    Article  CAS  Google Scholar 

  6. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227–337.

    Article  Google Scholar 

  7. Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on cardiovascular events and death. N. Engl J Med 2021;385:1067–77.

    Article  CAS  Google Scholar 

  8. Blumenthal JA, Hinderliter AL, Smith PJ, Mabe S, Watkins LL, Craighead L, et al. Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation 2021;144:1212–26.

    Article  CAS  Google Scholar 

  9. Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. QUARTET investigators. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet 2021;398:1043–52.

    Article  Google Scholar 

  10. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. ESC scientific document group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.

    Article  CAS  Google Scholar 

  11. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

    Article  Google Scholar 

  12. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381:1609–20.

    Article  CAS  Google Scholar 

  13. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380:539–48.

    Article  CAS  Google Scholar 

  14. Jackson AM, Jhund PS, Anand IS, Düngen HD, Lam CSP, Lefkowitz MP, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42:3741–52.

    Article  CAS  Google Scholar 

  15. Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209.

    Article  Google Scholar 

  16. Mahfoud F, Kieble M, Enners S, Werning J, Laufs U, Millenaar D, et al. “Dear doctor” warning letter (rote-hand-brief) on hydrochlorothiazide and its impact on antihypertensive prescription. Dtsch Arztebl Int. 2020;117:687–8.

    PubMed  PubMed Central  Google Scholar 

  17. Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M, et al. Blood pressure lowering treatment trialists’ collaboration. antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncol. 2021;22:558–70.

    Article  CAS  Google Scholar 

  18. MacIntyre IM, Turtle EJ, Farrah TE, Graham C, Dear JW, Webb DJ. PATH-BP (Paracetamol in hypertension–blood pressure) investigators*. regular acetaminophen use and blood pressure in people with hypertension: The PATH-BP trial. Circulation. 2022;145:416–23.

    Article  CAS  Google Scholar 

  19. Williams CM, Maher CG, Latimer J, McLachlan AJ, Hancock MJ, Day RO, et al. Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet. 2014;384:1586–96.

    Article  CAS  Google Scholar 

  20. Lauder L, Azizi M, Kirtane AJ, Böhm M, Mahfoud F. Device-based therapies for arterial hypertension. Nat Rev Cardiol. 2020;17:614–28.

    Article  Google Scholar 

  21. Mahfoud F, Schlaich MP, Lobo MD. Device therapy of hypertension. Circ Res. 2021;128:1080–99.

    Article  CAS  Google Scholar 

  22. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444–51.

    Article  Google Scholar 

  23. Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346–55.

    Article  Google Scholar 

  24. Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. RADIANCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476–86.

    Article  CAS  Google Scholar 

  25. Mahfoud F, Townsend RR, Kandzari DE, Kario K, Schmieder RE, Tsioufis K, et al. Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol. 2021;77:2909–19.

    Article  CAS  Google Scholar 

  26. Schmieder RE, Mahfoud F, Mancia G, Azizi M, Böhm M, Dimitriadis K, et al. Members of the ESH working group on device-based treatment of hypertension. European society of hypertension position paper on renal denervation 2021. J Hypertens. 2021;39:1733–41.

    Article  CAS  Google Scholar 

  27. Mahfoud F, Galle J, Schunkert H, Schmieder R, Rump L, Limbourg F, et al. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von “Renale-Denervations-Zentren (RDZ)”—Update. Kardiologe. 2021;15:463–70.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Felix Götzinger, Michael Kunz.

Authors and Affiliations

  1. Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital Saarland, Saarland University, 66424, Homburg, Germany

    Felix Götzinger, Michael Kunz, Lucas Lauder, Michael Böhm & Felix Mahfoud

Authors
  1. Felix Götzinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Kunz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lucas Lauder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Felix Mahfoud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felix Götzinger.

Ethics declarations

Conflict of interest

FG is supported by the German Heart Foundation/German Foundation for Heart Research. LL received speaker honoraria from Medtronic and ReCor Medical. MB is supported by Abbott, Amgen, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Deutsche Forschungsgemeinschaft (DFG, SFB TRR219, S-01, M-03, M-05), Medtronic, Novartis, ReCor Medical, Servier and Vifor. FM is supported by Deutsche Gesellschaft für Kardiologie (DGK) and Deutsche Forschungsgemeinschaft (SFB TRR219) as well as by the German Heart Foundation/German Foundation for Heart Research. He has received scientific support and speaker honoraria from Bayer, Boehringer Ingelheim, Medtronic and ReCor Medical. The other authors do not have any conflicts of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: In the original publication of the article, ref. [11–13] were incorrectly published.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Götzinger, F., Kunz, M., Lauder, L. et al. Arterial hypertension - clinical trials update 2022. Hypertens Res 45, 1140–1146 (2022). https://doi.org/10.1038/s41440-022-00931-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-022-00931-2

Keywords

This article is cited by

Search

Advanced search

Quick links